12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ARRY-520: Additional Phase Ib data

Data from 9 evaluable patients with relapsed or refractory MM who are refractory or intolerant to bortezomib and ineligible for autologous stem cell transplant in the first 2 cohorts of an investigator-sponsored, open-label, dose-escalation, U.S. Phase Ib trial showed that IV ARRY-520 plus carfilzomib produced 1 complete/near complete response, 1 partial response and 3 minimal responses, plus 2 cases of stable disease. The MTD has not yet been reached. There was 1 dose-limiting toxicity (DLT) of influenza pneumonia in...

Read the full 373 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >